MA32947B1 - Piperidines substitues par aroylamino et heteroaroylamino comme inhibiteurs de glyt-1 - Google Patents

Piperidines substitues par aroylamino et heteroaroylamino comme inhibiteurs de glyt-1

Info

Publication number
MA32947B1
MA32947B1 MA33992A MA33992A MA32947B1 MA 32947 B1 MA32947 B1 MA 32947B1 MA 33992 A MA33992 A MA 33992A MA 33992 A MA33992 A MA 33992A MA 32947 B1 MA32947 B1 MA 32947B1
Authority
MA
Morocco
Prior art keywords
alkyl
inferior
aryl
halogen
piperidine
Prior art date
Application number
MA33992A
Other languages
Arabic (ar)
English (en)
Inventor
Sabine Kolczewski
Emmanuel Pinard
Henri Stalder
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA32947B1 publication Critical patent/MA32947B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN COMPOSÉ DE LA FORMULE GÉNÉRALE (I) DANS LAQUELLE R1 EST HYDROGÈNE, ALKYLE INFÉRIEUR, CD3, -(CH2)N-CHO, -(CH2)N-O-ALKYLE INFÉRIEUR, -(CH2)N-OH, -(CH2)N-CYCLOALKYLE OU EST HÉTÉROCYCLOALKYLE ; R2 EST HYDROGÈNE, HALOGÈNE, HYDROXY, ALKYLE INFÉRIEUR, DI(ALKYLE INFÉRIEUR), -OCH2-O-ALKYLE INFÉRIEUR OU ALCOXY INFÉRIEUR ; OU LE NOYAU PIPÉRIDINE FORME CONJOINTEMENT AVEC R2 UN NOYAU SPIRO, CHOISI PARMI 4-AZASPIRO[2.5]OCT-6-YLE ; AR EST ARYLE OU HÉTÉROARYLE, QUI EST FACULTATIVEMENT SUBSTITUÉ PAR UN, DEUX OU TROIS SUBSTITUANTS, CHOISIS PARMI HALOGÈNE, ALKYLE INFÉRIEUR, ALKYLE INFÉRIEUR SUBSTITUÉ PAR HALOGÈNE, ALCOXY INFÉRIEUR SUBSTITUÉ PAR HALOGÈNE, CYCLOALKYLE, ALCOXY INFÉRIEUR, S-ALKYLE INFÉRIEUR, HÉTÉROARYLE, HÉTÉROCYCLOALKYLE OU PAR PHÉNYLE FACULTATIVEMENT SUBSTITUÉ PAR R', ET R' EST HALOGÈNE, ALKYLE INFÉRIEUR, ALCOXY INFÉRIEUR OU ALCOXY INFÉRIEUR SUBSTITUÉ PAR HALOGÈNE, OU EST HÉTÉROARYLE ; R EST ALKYLE INFÉRIEUR, CYCLOALKYLE, HÉTÉROCYCLOALKYLE, ARYLE OU HÉTÉROARYLE, L'ARYLE ET L'HÉTÉROARYLE ÉTANT FACULTATIVEMENT SUBSTITUÉS PAR UN OU DEUX R' ; N REPRÉSENTE 0, 1, 2 OU 3 ; OU UN SEL D'AJOUT D'ACIDE DE QUALITÉ PHARMACEUTIQUE ACCEPTABLE DE CELUI-CI, UN MÉLANGE RACÉMIQUE DE CELUI-CI OU SON ÉNANTIOMÈRE ET/OU ISOMÈRE OPTIQUE CORRESPONDANT. EN OUTRE, LA PRÉSENTE INVENTION CONCERNE DES COMPOSITIONS PHARMACEUTIQUES CONTENANT LES COMPOSÉS DE LA FORMULE I ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES NEUROLOGIQUES ET NEUROPSYCHIATRIQUES.
MA33992A 2009-01-27 2010-01-19 Piperidines substitues par aroylamino et heteroaroylamino comme inhibiteurs de glyt-1 MA32947B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09151382 2009-01-27
PCT/EP2010/050551 WO2010086251A1 (fr) 2009-01-27 2010-01-19 Pipéridines substitués par aroylamino et hétéroaroylamino comme inhibiteurs de glyt-1

Publications (1)

Publication Number Publication Date
MA32947B1 true MA32947B1 (fr) 2012-01-02

Family

ID=41718529

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33992A MA32947B1 (fr) 2009-01-27 2010-01-19 Piperidines substitues par aroylamino et heteroaroylamino comme inhibiteurs de glyt-1

Country Status (24)

Country Link
US (2) US20100197715A1 (fr)
EP (1) EP2391603B1 (fr)
JP (1) JP5552494B2 (fr)
KR (1) KR101289577B1 (fr)
CN (1) CN102292320B (fr)
AR (1) AR075160A1 (fr)
AU (1) AU2010209816A1 (fr)
BR (1) BRPI1007410A2 (fr)
CA (1) CA2746967A1 (fr)
CO (1) CO6341621A2 (fr)
CR (1) CR20110348A (fr)
EC (1) ECSP11011196A (fr)
ES (1) ES2445143T3 (fr)
IL (1) IL213672A0 (fr)
MA (1) MA32947B1 (fr)
MX (1) MX2011007272A (fr)
NZ (1) NZ593279A (fr)
PE (1) PE20120500A1 (fr)
RU (1) RU2517701C2 (fr)
SG (1) SG173116A1 (fr)
TW (1) TWI403322B (fr)
UA (1) UA104611C2 (fr)
WO (1) WO2010086251A1 (fr)
ZA (1) ZA201104237B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010209816A1 (en) 2009-01-27 2011-08-11 F. Hoffmann-La Roche Ag Aroylamino - and heteroaroylamino-substituted piperidines as GlyT-1 inhibitors
KR20120109292A (ko) * 2009-06-24 2012-10-08 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Ｎ-치환-시클릭 아미노 유도체
US20140155419A1 (en) * 2011-07-29 2014-06-05 Erkan Baloglu Compounds and methods
US9012489B2 (en) 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
WO2013063214A1 (fr) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
EP4054551A4 (fr) * 2019-11-07 2024-03-20 Univ Illinois Inhibiteurs d'entrée virale de la grippe
CN114478360B (zh) * 2022-02-10 2023-08-15 江苏海洋大学 一种苯甲酰胺类衍生物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2600557A1 (de) * 1976-01-09 1977-07-14 Delmar Chem 4-aryl-3/4-amino/hydroxy-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
CA2406652A1 (fr) 2000-04-20 2001-11-01 Nps Allelix Corp. Aminopiperidines
WO2002080928A1 (fr) * 2001-04-03 2002-10-17 Merck & Co., Inc. Antagonistes de nmda/nr2b nonaryl-heterocyclo amidyle n-substitues
ES2271844T3 (es) * 2003-02-17 2007-04-16 F. Hoffmann-La Roche Ag Derivados de piperidina-bencenosulfonamida.
FR2861074B1 (fr) * 2003-10-17 2006-04-07 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861071B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique
DE602004010419T2 (de) * 2003-10-23 2008-10-09 F. Hoffmann-La Roche Ag Triazaspiropiperidinderivate zur verwendung als glyt-1-inhibitoren bei der behandlung von neurologischen und neuropsychiatrischen erkrankungen
WO2008093737A1 (fr) * 2007-01-31 2008-08-07 Dainippon Sumitomo Pharma Co., Ltd. Dérivé d'amide
UA41251U (ru) * 2008-12-26 2009-05-12 Яков Семенович Песиков Способ лечения алкоголизма
AU2010209816A1 (en) 2009-01-27 2011-08-11 F. Hoffmann-La Roche Ag Aroylamino - and heteroaroylamino-substituted piperidines as GlyT-1 inhibitors

Also Published As

Publication number Publication date
CN102292320A (zh) 2011-12-21
IL213672A0 (en) 2011-07-31
PE20120500A1 (es) 2012-05-04
RU2517701C2 (ru) 2014-05-27
TWI403322B (zh) 2013-08-01
WO2010086251A1 (fr) 2010-08-05
ES2445143T3 (es) 2014-02-28
US20130158050A1 (en) 2013-06-20
UA104611C2 (en) 2014-02-25
CO6341621A2 (es) 2011-11-21
JP5552494B2 (ja) 2014-07-16
CA2746967A1 (fr) 2010-08-05
JP2012515744A (ja) 2012-07-12
EP2391603A1 (fr) 2011-12-07
KR101289577B1 (ko) 2013-07-24
NZ593279A (en) 2013-03-28
ECSP11011196A (es) 2011-08-31
AR075160A1 (es) 2011-03-16
MX2011007272A (es) 2011-08-08
SG173116A1 (en) 2011-08-29
US9067911B2 (en) 2015-06-30
US20100197715A1 (en) 2010-08-05
TW201032803A (en) 2010-09-16
EP2391603B1 (fr) 2014-01-08
KR20110107863A (ko) 2011-10-04
BRPI1007410A2 (pt) 2016-02-16
ZA201104237B (en) 2012-02-29
RU2011134960A (ru) 2013-03-10
CN102292320B (zh) 2014-07-02
CR20110348A (es) 2011-09-06
AU2010209816A1 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
MA32947B1 (fr) Piperidines substitues par aroylamino et heteroaroylamino comme inhibiteurs de glyt-1
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
CR20110049A (es) Derivados de benzazepina y su uso como antagonistas de histamina h3
WO2008051533A3 (fr) Composés de benzimidazole
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
MY160443A (en) Nitrogen-containing heterocyclic compound and agricultural fungicide
TNSN08372A1 (en) Heterocyclic amides for use as pharmaceuticals
MX342064B (es) Novedoso compuesto de imidazo-oxazina o sal del mismo.
CR20120053A (es) Compuestos y metodos inhibidores de jak de pirazolopirimidina
EP2597088A4 (fr) Antagoniste des récepteurs p2x4
MX354021B (es) Derivados de 5-fluor-4-imino-3- (sustituido) -3,4-dihidropirimidin -2 (1h) ona.
ES2567311T3 (es) 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP
WO2013076315A3 (fr) Composés substitués de n-(tétrazol-5-yl)- et n-(triazol-5-yl) arylcarboxamides et leur utilisation comme herbicides
GEP20125637B (en) Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
IN2012DN00770A (fr)
ES2553030T3 (es) Compuestos plaguicidas
ZA201002139B (en) New compounds as adenosine a1 receptor antagonists
EA201590438A1 (ru) 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы
CO6321269A2 (es) Derivados de benzoxazinona que actuan como agonistas de receptores adrenergicos beta 2 para el tratamiento de transtornos respiratorios
MX2011011281A (es) Compuesto de carbinol que tiene un enlazante heterociclico.
MX2012006696A (es) Derivados de 3, 4, 4a, 10b-tetrahidro-1h-tiopirano-[4, 3-c]-isoqunolina.
EA201200903A1 (ru) Гербицидно активные заместители 2-(замещенного-фенила)циклопентан-1,3-диона
RS54413B1 (en) [4- (5-AMINOMETHYL-2-FLUORO-PHENYL) -PIPERIDIN-1-IL] - [7-FLUORO-1- (2-METHOXY-ETHYL) -4TRIFLUOROMETOXY-1H-INDOL-3-IL] METHANONE AS INHIBITOR MASTOCYT TRIPTASES
PH12014502663B1 (en) Aromatic heterocyclic derivative and pharmaceutical
RS54248B1 (en) NEW UNITS AS LISTS OF HISTAMINE H3 RECEPTORS